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Objective: Laron syndrome (LS) is a rare, autosomal recessive disorder in humans caused by loss-of-function mutations of the growth hormone
receptor (GHR) gene. To establish a large animal model for LS, pigs with GHR knockout (KO) mutations were generated and characterized.
Methods: CRISPR/Cas9 technology was applied to mutate exon 3 of the GHR gene in porcine zygotes. Two heterozygous founder sows with a 1-
bp or 7-bp insertion in GHR exon 3 were obtained, and their heterozygous F1 offspring were intercrossed to produce GHR-KO, heterozygous GHR
mutant, and wild-type pigs. Since the latter two groups were not signiﬁcantly different in any parameter investigated, they were pooled as the GHR
expressing control group. The characterization program included body and organ growth, body composition, endocrine and clinical-chemical
parameters, as well as signaling studies in liver tissue.
Results: GHR-KO pigs lacked GHR and had markedly reduced serum insulin-like growth factor 1 (IGF1) levels and reduced IGF-binding protein 3
(IGFBP3) activity but increased IGFBP2 levels. Serum GH concentrations were signiﬁcantly elevated compared with control pigs. GHR-KO pigs had
a normal birth weight. Growth retardation became signiﬁcant at the age of ﬁve weeks. At the age of six months, the body weight of GHR-KO pigs
was reduced by 60% compared with controls. Most organ weights of GHR-KO pigs were reduced proportionally to body weight. However, the
weights of liver, kidneys, and heart were disproportionately reduced, while the relative brain weight was almost doubled. GHR-KO pigs had a
markedly increased percentage of total body fat relative to body weight and displayed transient juvenile hypoglycemia along with decreased
serum triglyceride and cholesterol levels. Analysis of insulin receptor related signaling in the liver of adult fasted pigs revealed increased
phosphorylation of IRS1 and PI3K. In agreement with the loss of GHR, phosphorylation of STAT5 was signiﬁcantly reduced. In contrast, phos-
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Original Articleexpression and activation in GHR-KO pigs. In addition, increased mTOR phosphorylation was observed in GHR-KO liver samples, and phos-
phorylation studies of downstream substrates suggested the activation of mainly mTOR complex 2.
Conclusion: GHR-KO pigs resemble the pathophysiology of LS and are an interesting model for mechanistic studies and treatment trials.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Laron syndrome (LS) is a rare, autosomal recessive, hereditary dis-
order caused by loss-of-function mutations in the growth hormone
receptor (GHR) gene (https://www.omim.org/entry/600946), initially
described as a syndrome of primary growth hormone (GH) resistance
or insensitivity ([1]; reviewed in [2,3]). As a consequence, LS patients
have low levels of insulin-like growth factor 1 (IGF1) and e due to the
lack of feedback inhibition of GH secretion e high levels of GH [3]. A
few hundred cases of LS have been reported world-wide, caused by a
variety of GHR mutations (reviewed in [4]). Among them is an isolated,
more homogeneous population of GHR deﬁcient patients in Ecuador
with only two distinct mutations of the GHR gene [5e7].
The main clinical feature is short stature. In addition, LS patients may
exhibit reduced muscle strength and endurance, hypoglycemia in in-
fancy, delayed puberty, obesity, and distinct facial features, including a
protruding forehead, sunken bridge of the nose, and blue sclerae
(reviewed in [3,8]). The standard treatment of LS is long-term appli-
cation of recombinant IGF1, which increases growth velocity and im-
proves adult height, but it may lead to a spectrum of side effects, in
particular hypoglycemia ([9,10]; reviewed in [11]).
A particularly interesting observation in LS patients is their reduced
incidence of malignancies ([12,13]; reviewed in [8]). In addition, LS
patients from the cohort in Ecuador have been shown to be protected
against the development of type 2 diabetes despite severe obesity [7].
Although mechanistic studies have been performed in cell lines derived
from LS patients and healthy controls [7,14], animal models are of
pivotal importance for understanding the pathophysiology of LS in vivo.
In particular, GHR-deﬁcient mice [15] have provided new insights into
the consequences of GH insensitivity for body and organ growth, body
composition, endocrine and metabolic functions, and reproduction, as
well as aging and life expectancy (reviewed in [16]). More recently,
inducible/tissue-speciﬁc Ghr knockout (KO) mouse models have hel-
ped to deﬁne the speciﬁc roles of GHR in liver, muscle, and adipose
tissue and revealed interesting differences compared with constitutive
Ghr KO mice [17,18]. However, due to their small size, short life ex-
pectancy and physiological differences compared with humans, ﬁnd-
ings from mouse models may be difﬁcult to extrapolate to the clinical
situation of LS patients. In general, genetically tailored pig models are
useful to bridge the gap between proof-of-concept studies in rodent
models and clinical studies in patients (reviewed in [19,20]). Thus, we
have developed a GHR-deﬁcient (GHR-KO) pig model and show that it
resembles important aspects of LS pathophysiology and reveals
altered activation of signaling cascades in the liver.
2. MATERIALS AND METHODS
2.1. Generation of GHR mutant pigs using CRISPR/Cas
All animal procedures in this study were approved by the responsible
animal welfare authority (Regierung von Oberbayern; permission 55.2-
1-54-2532-70-12) and performed according to the German Animal
Welfare Act and Directive 2010/63/EU on the protection of animals
used for scientiﬁc purposes.114
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RNA (sgRNA) speciﬁc for exon 3 sequence 50-TTCATGCCACTGGACA-
GATG-30, a corresponding oligonucleotide was cloned into the pEX-A-
U6-gRNA vector as described previously [21]. Cas9 mRNA and sgRNA
were in vitro-transcribed using the Ambion Maxiscript SP6 kit (Thermo
Fisher Scientiﬁc).
Porcine zygotes (German landrace background) were produced in vitro
as described previously [22], and Cas9 mRNA (50 ng/mL) and sgRNA
(100 ng/mL) was injected into their cytoplasm 8.5e9.5 h after in vitro
fertilization. Recipient gilts were synchronized in the estrous cycle by
oral administration of 4 mL Altrenogest (Regumate; MSD Animal
Health) for 15 days, followed by intramuscular injection of 750 IU ECG
(Intergonan; MSD Animal Health) and 750 IU HCG (Ovogest; MSD
Animal Health) after an additional 24 and 104 h, respectively. Embryo
transfer was performed laparoscopically into one oviduct [23,24].
Pregnancy was conﬁrmed by ultrasonographic examination ﬁrst on day
21 and again 4e6 weeks later.
Genomic DNA was isolated from tail tips of piglets using the Wizard
DNA Extraction Kit (Promega). GHR mutations were detected by
sequencing a GHR exon 3 PCR product obtained using primers
GHR_Fw 50-acc gct ctg aag ctg tga cc-30 and GHR_Rv 50-cac cct cag
ata ctc tca tgc-30. Based on the detected mutations, an XcmI restriction
fragment length polymorphism assay was established, yielding frag-
ments of 203 bp and 441 bp for wild-type GHR and a single fragment
of 644 bp for the mutated GHR sequence.
Two female founder animals with different frameshift mutations were
mated with wild-type boars to generate heterozygous F1 offspring.
Heterozygous offspring of the same founder were intercrossed to
obtain homozygous animals (GHR-KO) with the respective GHR mu-
tations. The resulting pedigrees are shown in Suppl. Fig. 1.
2.2. Ligand immunostaining of porcine GHR
Liver and kidney tissue of GHR-KO and control pigs was ﬁxed overnight
in 4% formaldehyde and routinely embedded in parafﬁn. Parafﬁn
sections were dewaxed, and endogenous peroxidase and biotin were
blocked with 1% H2O2 in Tris-buffered saline (TBS) for 15 min and by
using the avidin/biotin blocking kit (no. SP-2001; Vector Laboratories),
respectively. After blocking with 0.5% ﬁsh gelatin for 30 min, the slides
were incubated in 0.5 mg/mL recombinant rat GH (no. 16343667,
ImmunoTools) in 0.2% ﬁsh gelatin solution overnight at 4 C. They
were then washed 3 times for 5 min in TBS and incubated in goat anti-
rat GH polyclonal antibody solution (dilution 1:2,400, no. AF1566, R&D
Systems) for 6 h at room temperature. After 3 washing steps in TBS
(10 min each), the slides were incubated in biotinylated rabbit anti-goat
IgG solution (dilution 1:100, no. BA-5000, Vector Laboratories) for 1 h
at room temperature, washed 3 times for 10 min in TBS, and ﬁnally
incubated with horseradish peroxidase-labelled avidin biotin complex
for 30 min (no. PK-6100, VECTASTAIN Elite ABC-Peroxidase kit, Vector
Laboratories). Immunoreactivity was visualized using 3,30-dia-
minobenzidine tetrahydrochloride dihydrate (DAB) (brown color). Nu-
clear counterstaining was performed with Mayer’s hemalum (blue
color). As speciﬁcity controls for the ligand immunohistochemistry
assay, rat GH as well as rat GH plus primary antibody were omitted.MOLECULAR METABOLISM 11 (2018) 113e128
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2.3. Blood collection
Animals were fasted overnight (16 h) before blood collection from the
jugular vein. After clotting for 30 min at room temperature, serum was
separated by centrifugation (1200  g) for 20 min at 6 C and stored
at 80 C until analysis. For repeated blood sampling required to
analyze GH secretion proﬁles, central venous catheters (Argon Care-
ﬂow; Merit Medical) were surgically inserted through the external ear
vein. Blood samples were collected every 30 min for 9 h, starting at 11
a.m., and processed for serum collection as described above. During the
test, the animals were fed regularly and had free access to water.
2.4. Clinical chemistry, hormone assays, IGFBP ligand blot analysis
Clinical-chemical parameters in serum were determined using a Cobas
311 system (Hitachi) or an AU480 autoanalyzer (Beckman-Coulter)
and adapted reagents from Roche Diagnostics or Beckman-Coulter,
respectively. Serum GH concentrations were measured by an ELISA for
rat/mouse GH (EZRMGH-45K; Merck) that cross-reacts with porcine GH.
To calculate the area under the GH curve, values below the quantiﬁcation
limit of the assay (<0.07 ng/mL) were arbitrarily set to 0.07 ng/mL. IGF1
levels in serum were determined by RIA after dissociation of IGF1 from
IGFBPs by acidiﬁcation and blocking the IGF1 binding sites with an
excess of IGF2 [25]. IGFBP ligand blot analysis of serum samples was
performed as described previously [26] using serial dilutions of re-
combinant human IGFBP3 (41/38 kDa), IGFBP2 (32 kDa), IGFBP5
(29 kDa) and IGFBP4 (24 kDa) for quantiﬁcation. Plasma insulin was
determined using a species-speciﬁc RIA (Merck Millipore) as previously
described [27]. Blood glucose levels were determined immediately using
a Precision Xceed glucometer and Precision XtraPlus test strips
(Abbott) [28]. Serum leptin levels were measured using a multi-species
leptin radioimmunoassay (Cat. # XL-85K; EMD Millipore Corporation)
that has been validated for porcine samples [29].
2.5. Growth parameters and body composition
Body weight and body length (distance between tip of the snout and tail
root in straightened animals) of GHR-KO and control pigs were
determined at weekly intervals. Relative body length was calculated by
dividing the body length by the cube root of the body weight to retain
the same dimensions. Since not all animals could be weighed/
measured at exactly the same ages, raw data were adjusted by linear
interpolation to deﬁned ages/time points.
The percentage of total body fat was determined in 6-month-old GHR-
KO and control pigs using dual-energy X-ray absorptiometry (DXA;
Lunar iDXA, GE Healthcare) as previously described [30]. In addition,
magnetic resonance imaging (MRI; Magnetom Open, Siemens) [31]
was performed to visualize and determine the muscle to fat ratio as
the area of longissimus dorsi muscle divided by the area of its overlying
back fat at the last rib.
2.6. Necropsy
GHR-KO and control pigs were euthanized at 6 months of age under
anesthesia by intravenous injection of T61 (Intervet) and immediately
subjected to necropsy. Organs were dissected and weighed to the
nearest mg. Tissue samples were collected as described previously [32]
and routinely ﬁxed in neutral buffered formalin solution (4%) for 24 h or
frozen immediately on dry ice and stored at 80 C for molecular
proﬁling. Formalin-ﬁxed tissue specimens were embedded in parafﬁn.
Muscle sections were stained with hematoxylin and eosin (H&E).
2.7. Immunoblot analysis of signaling cascades
The concentrations and phosphorylation status of GHR-related
signaling molecules in the liver were evaluated by Western blotMOLECULAR METABOLISM 11 (2018) 113e128  2018 The Authors. Published by Elsevier GmbH. This is a
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were homogenized in Laemmli extraction buffer, and the protein
content was determined by the bicinchoninic acid protein assay. Forty
micrograms of total protein was separated by SDS-PAGE and trans-
ferred to PVDF membranes (Millipore) by electro-blotting. Membranes
were washed in TBS with 0.1% Tween-20 and blocked in 5% w/v fat-
free milk powder (Roth) for 1 h. The membranes were then washed
again and incubated in 5% w/v BSA (Roth) solution with the appro-
priate primary antibodies overnight at 4 C. The antibodies and con-
centrations used are listed in Suppl. Table 1. After washing, the
membranes were incubated in 5% w/v fat-free milk powder solution
with the secondary antibody (donkey anti-rabbit; 1:2000; GE Health-
care) for 1 h. Bound antibodies were detected using the ECL Advance
Western Blotting Detection Kit (GE Healthcare) and appropriate ﬁlms
from the same supplier. Band intensities were quantiﬁed using the
ImageQuant software package (GE Healthcare).
2.8. Statistical analyses
Longitudinal data for body weight and body length or relative body length
respectively were analyzed using PROC MIXED (SAS 8.2), taking the ef-
fects of pig line (#2529; #2533), group (GHR-KO; control), sex, age, and
interaction group*age into account. Least squares means (LSMs) and
standards errors (SEs) of LSMs were calculated for group*age and
compared using Student’s t-test. Data for glucose homeostasis and
serum lipid concentrations were analyzed using PROC GLM (SAS 8.2),
taking the effects of group, sex, age and the interaction group*age into
account. LSMs and SEs were calculated for group*age and compared
using Student’s t-test. Body composition, organ weight and clinical-
chemical data were analyzed using PROC GLM taking the effects of group
and sex into account. LSMs and SEs were calculated for groups and
compared using Student’s t-test. IGFBP ligand blot and Western immu-
noblot data were evaluated for signiﬁcant differences between GHR-KO
and control pigs using the Mann-Whitney U test.
3. RESULTS
3.1. Generation of a growth hormone receptor-deﬁcient pig model
We employed CRISPR/Cas9 technology to generate GHR knockout (GHR-
KO) pigs as a large animal model for Laron syndrome (LS). In vitro-
transcribed RNA encoding Cas9 and sgRNA speciﬁc for GHR exon 3 was
injected into in vitro fertilized porcine oocytes, which were transferred to
recipient gilts. In total, 8 piglets were born, of which 3 showedmonoallelic
mutations in the GHR gene. Two female founder animals carried mono-
allelic insertions of 1 bp (#2529) or 7 bp (#2533) (Figure 1A). The two
founder animals were mated with wild-type boars to establish pedigrees
for phenotypic analyses of GHR-deﬁcient (GHR-KO) vs. GHR-expressing
F2 animals (Suppl. Fig. 1). The two lines were kept separate except in
one experiment to test the fertility of GHR-KO pigs. Wild-type, heterozy-
gous, and GHR-KO littermates were identiﬁed by PCR and restriction
fragment length polymorphisms of the mutated and wild-type GHR alleles
(Figure 1B). Since we did not observe signiﬁcant differences between
heterozygous GHR mutant and wild-type animals (Suppl. Fig. 2), they
were pooled and used as the GHR-expressing control group.
3.2. Homozygous frameshift mutations in GHR exon 3 result in GHR
deﬁciency
The insertion of 1 bp (#2529) or 7 bp (#2533) leads to a shift in the
reading frame in GHR exon 3. The mutant GHR transcripts encode the
18-aa signal peptide and 51 aa of the extracellular GHR domain, fol-
lowed by an 18-aa or a 20-aa missense sequence and premature
termination codon after 87 aa (#2529) or 89 aa (#2533) (Figure 1C).n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 115
Figure 1: Generation of a GHR-deﬁcient pig model using CRISPR/Cas technology. (A) Partial DNA sequence of GHR exon 3. The sgRNA binding site is indicated in blue and the
protospacer adjacent motif (PAM) in green. Insertions (red) of 1 bp (founder #2529) or 7 bp (founder #2533) lead to a shift of the reading frame. WT ¼ wild type. (B) Restriction
fragment length polymorphism analysis to detect the WT GHR sequence as well as monoallelic (Het) and biallelic (KO) mutations. (C) Partial amino acid sequences encoded by the
WT and mutant GHR alleles. The signal peptide is shown in gray, WT GHR aa sequence in black (aa encoded by adjacent non-symmetrical exons in blue), missense aa sequence in
red, and the premature termination codon as an asterisk. (D) Ligand immunohistochemistry demonstrating the absence of functional GHR (brown staining in control) in GHR-KO
pigs. Chromogen: DAB; counterstain: Mayer’s hemalum; bar ¼ 10 mm.
Original ArticleThe presence of GHR was investigated in liver and kidney sections
since these tissues naturally express high levels of GHR [34]. To
evaluate GH binding, the sections were incubated with recombinant
GH, and bound GH was detected using speciﬁc antibodies. This ligand
immunohistochemistry approach showed strong GH binding in control
tissues, while GH binding was absent in tissue sections from GHR-KO
animals (Figure 1D).
3.3. Decreased serum IGF1 and IGFBP3, and increased IGFBP2 in
GHR-KO pigs
GHR-KO pigs of all ages showed a marked reduction in serum insulin-
like growth factor 1 (Figure 2A,B). IGF binding proteins (IGFBPs) were
evaluated by ligand blot analysis in 6-month-old animals using a
dilution series of recombinant human IGFBPs for quantiﬁcation
(Figure 2C). IGFBP3 was signiﬁcantly decreased in GHR-KO pigs
(426 41 mg/L vs. 1775 205 mg/L in control animals; p< 0.0001),
while IGFBP2 was signiﬁcantly increased (799  53 mg/L vs.
607  66 mg/L in control animals; p ¼ 0.0272) (Figure 2D).
3.4. GHR-KO pigs have high levels of circulating GH
To evaluate effects of GHR deﬁciency on the pulsatile secretion of GH,
we collected serial blood samples at 30-min intervals over a period of
9 h (starting at 11 a.m.) from ﬁve female and one male 9-month-old
GHR-KO pigs and from six age-matched female controls. Serum GH
levels of GHR-KO pigs were high with partially preserved pulsatility
(area under the GH curve was increased 6.8-fold in GHR-KO compared
with control pigs), indicating a disturbance in the negative feedback
control of GH secretion (Figure 2E,F; Suppl. Fig. 3).116
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The birth weight of GHR-KO piglets did not differ from control litter-
mates. First signiﬁcant growth retardation became obvious at ﬁve
weeks of age (p ¼ 0.045), leading to a 62% reduction in body weight
of 6-month-old GHR-KO pigs (33.0  1.5 kg) compared with age-
matched control animals (86.2  1.1 kg; p < 0.0001)
(Figure 3A,B). Body length at birth did not differ between GHR-KO and
control piglets (33.9  1.4 cm vs. 37.3  1 cm; p ¼ 0.4068). Sig-
niﬁcant differences in body length appeared at four weeks of age
(52.2  1.4 cm in GHR-KO vs. 60.3  1 cm in control animals;
p < 0.0001). At six months of age, the body length of GHR-KO pigs
was reduced by 27% compared with control pigs (100.6  1.6 cm vs.
138.1 1.4 cm; p< 0.0001) (Figure 3C). Up to an age of four months,
weight gain was more affected than linear growth by GHR deﬁciency,
as indicated by an increased relative body length (body length divided
by the cube root of body weight) of GHR-KO pigs (Figure 3D). No
growth parameters exhibited signiﬁcant sex-related differences.
3.6. GHR-KO pigs show an increased proportion of body fat and a
reduced ratio of muscle to fat tissue
DXA analysis revealed a markedly increased percentage of total body
fat in 6-month-old GHR-KO pigs (21.5  0.7% vs. 11.4  0.5% in
age-matched control animals; p < 0.0001) (Figure 4A). While female
pigs in the control group displayed signiﬁcantly higher body fat content
than male pigs (13.2  0.7% vs. 9.6  0.7%; p ¼ 0.0009), no sex-
related differences were observed in GHR-KO pigs (22.9  1% in
males vs. 22  1% in females; p ¼ 0.4530). To determine the ratio of
muscle to fat tissue, MRI scans were performed at the location of theMOLECULAR METABOLISM 11 (2018) 113e128
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Figure 2: Serum IGF1, IGFBP and GH concentrations of GHR-KO compared with control pigs. (A) Scatter plot of serum IGF1 levels of GHR-KO and control pigs over time. (B) Means
and standard deviations of all serum IGF1 values displayed in panel A (GHR-KO: n ¼ 42; control: n ¼ 69). (C) Representative IGFBP ligand blot. Right lane displays recombinant
human IGFBP3 (41/38 kDa), IGFBP2 (32 kDa), IGFBP5 (29 kDa) and IGFBP4 (24 kDa). (D) Quantiﬁcation of IGFBP3 and IGFBP2 in serum from GHR-KO (n ¼ 10) and control pigs
(n ¼ 12). The ﬁgure shows medians, 25th and 75th percentiles (box), and extremes (whiskers). (E) Representative GH secretion proﬁles of two female GHR-KO and two female
control pigs. (F) Area under the GH curve (AUC; means and standard deviations for 6 female GHR-KO and 5 female/1 male control pigs). AU ¼ arbitrary units. *p < 0.05;
***p < 0.001.last rib, and the volume ratio of the longissimus dorsi muscle and its
overlying back fat was calculated (Figure 4B,C). GHR-KO pigs showed
a signiﬁcantly reduced muscle to fat tissue ratio compared with control
pigs (3.0 0.6 vs. 8.2 0.4; p< 0.0001) (Figure 4B). No sex-related
differences were observed in this parameter (Suppl. Table 2). The MRI
ﬁndings were conﬁrmed upon necropsy, showing a marked increase in
the thickness of the subcutaneous fat tissue and a reduction in the size
of the longissimus dorsi muscle in GHR-KO pigs (Figure 4D,E). Histo-
logical sections of skeletal muscle samples from GHR-KO pigs revealed
markedly increased numbers of adipocyte section proﬁles between
muscle ﬁbers (Figure 4E).
3.7. Disproportionate organ growth of GHR-KO pigs
In 6-month-old GHR-KO pigs, absolute weights of all organs were
signiﬁcantly smaller than in age-matched control animals (Figure 5,
Suppl. Table 3). Most organ weights of GHR-KO pigs were reducedMOLECULAR METABOLISM 11 (2018) 113e128  2018 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comproportionally to body weight. However, the relative weights of liver
(73% of control animal relative liver weight; p ¼ 0.0005), kidneys
(73% of control animal relative kidney weight; p ¼ 0.0002) and heart
(87% of control animal relative heart weight; p ¼ 0.0119) were
signiﬁcantly reduced, while relative brain weight was doubled (200%
of control animal relative brain weight; p < 0.0001) (Figure 5,
Suppl. Table 3).
3.8. Male and female GHR-KO pigs are fertile
The ovaries of 6-month-old GHR-KO gilts did not show obvious
morphological differences from control ovaries. Mating of an 8-month-
old GHR-KO boar (line #2529) with a GHR-KO sow (line #2533) of the
same age resulted in a litter of 6 healthy GHR-KO piglets
(Suppl. Fig. 4A). Their birth weight tended to be reduced in comparison
to GHR-KO piglets derived from heterozygote  heterozygote matings
(on average 0.75 kg compared with 1.3 kg). However, the animalsn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 117
Figure 3: Body weight gain and growth of GHR-KO compared with control pigs. (A) GHR-KO pig (front) and control littermate aged 6 months. (B) Body weight gain. (C) Body length.
(D) Relative body length (body length divided by the cube root of body weight). These parameters were determined in 12 GHR-KO and 25 control pigs. Panels AeD show least
squares means (LSMs) and standard errors of LSMs estimated for group*age (see 2.8 for the statistical model). *p < 0.05; **p < 0.01; ***p < 0.001; ns ¼ not signiﬁcant.
Original Articleshowed catch-up growth and achieved a higher body weight at 6
months of age than GHR-KO offspring from heterozygous GHR-KO
parents (43.8 1.3 kg vs. 33.0 2.2 kg; p< 0.0001; Suppl. Fig. 4B).
3.9. GHR-KO pigs show transient hypoglycemia, while insulin
levels remain unaffected
Young GHR-KO pigs (12e15 weeks old) showed signiﬁcantly reduced
fasting blood glucose levels (41.5  3.8 mg/dL vs. 63.1  3.1 mg/dL
in age-matched control animals; p ¼ 0.0001), while this difference
disappeared in older animals (23e27 weeks) (Figure 6A). Fasting
serum insulin levels of GHR-KO pigs did not differ from control pigs at
any age (Figure 6B). In addition, the homeostatic model assessment
(HOMA) for evaluating insulin resistance was calculated from fasting
glucose and insulin concentrations. In agreement with their low fasting
blood glucose concentrations, HOMA-IR values of young GHR-KO pigs
tended to be reduced (0.25  0.20 vs. 0.76  0.19 in age-matched
control pigs; p ¼ 0.0635), but increased to 0.76  0.18 in the older
age group (p¼ 0.0839), when controls had a HOMA-IR of 0.43 0.20
(p ¼ 0.2584; Figure 6C). Analysis of variance revealed a signiﬁcant
(p < 0.05) interaction of group*age.
3.10. Serum lipid levels are reduced in young GHR-KO pigs
Young GHR-KO pigs (aged 12e15 weeks) revealed signiﬁcantly
decreased serum concentrations of triglycerides (23.2  6.8 mg/dL vs.
42.3  4.9 mg/dL in controls; p ¼ 0.021; Figure 6D), cholesterol
(70  3.5 mg/dL vs. 81.8  2.8 mg/dL in controls; p ¼ 0.0129;
Figure 6E), low-density lipoprotein (LDL)-cholesterol (42.8  2.7 mg/dL
vs. 50.1  2.1 mg/dL in controls; p ¼ 0.0392; Figure 6F) and high-
density lipoprotein (HDL)-cholesterol (29.0  1.6 mg/dL vs.
33.8  1.3 mg/dL in controls; p ¼ 0.0224; Figure 6G). In older GHR-
KO pigs (23e27 weeks), serum triglyceride, cholesterol and118
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while serum HDL-cholesterol levels were increased (32.5  1.3 mg/dL
vs. 28.6  1.0 mg/dL in controls; p ¼ 0.0272) (Figure 6DeG).
Excluding triglycerides, all investigated lipid parameters were signiﬁ-
cantly (p< 0.0002) affected by sex, with higher levels in female than in
male animals (Suppl. Table 4).
3.11. Additional alterations of clinical-chemical parameters in
GHR-KO pigs
To screen for changes in organ functions and metabolic pathways, a
broad spectrum of clinical-chemical parameters in serum of 6-month-
old GHR-KO and control pigs were analyzed. While all parameters
remained within physiological ranges, GHR-KO pigs displayed lower
levels of creatinine (91.2  6.5 mmol/L vs. 126.4  5.0 mmol/L in
controls; p ¼ 0.0004) but higher levels of urea (7.4  0.5 mmol/L vs.
4.3  0.3 mmol/L in controls; p < 0.0001) (Suppl. Table 5).
3.12. GHR-KO pigs display signiﬁcant changes in the activation of
hepatic signaling cascades
Since the liver is a major target tissue of insulin and GH, we evaluated
changes in associated signaling cascades by Western blot analyses of
liver samples from fasted 6-month-old GHR-KO and control animals.
The total amounts of insulin receptor (INSR) and of phosphorylated
INSR were unchanged in GHR-KO liver samples. In contrast, the
concentrations of total and phosphorylated insulin receptor substrate 1
(IRS1) were signiﬁcantly (p ¼ 0.0159) increased in liver samples from
GHR-KO vs. control pigs. The investigation of signal transducers
downstream of the INSR revealed signiﬁcantly increased phosphory-
lation of phosphoinositide 3 kinase (PI3K) and a trend (p ¼ 0.0635)
toward an increase in serine/threonine protein kinase AKT phosphor-
ylation in GHR-KO liver samples. Furthermore, a trend (p ¼ 0.0635)MOLECULAR METABOLISM 11 (2018) 113e128
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Figure 4: Body composition of 6-month-old GHR-KO compared with control pigs. (A) DXA analysis revealed a signiﬁcantly higher amount of total body fat in GHR-KO pigs. (B) The
calculated ratio of muscle to fat tissue from MRI images at the last rib revealed a signiﬁcant shift towards fat tissue in GHR-KO pigs (GHR-KO: n ¼ 12; control: n ¼ 25;
***p < 0.001). Panels A and B show least squares means (LSMs) and standard errors of LSMs estimated for the 2 groups (see 2.8 for the statistical model). (C) Representative
magnetic resonance images used to evaluate the volume of the longissimus dorsi muscle (mu) and its overlying back fat (ft) at the last rib in GHR-KO and control pigs. Note the
larger subcutaneous and visceral fat depots in GHR-KO pigs. (D) Representative macroscopic cross-sections of the ﬁrst lumbar vertebra, the two longissimus dorsi muscles and the
overlying back fat and skin. (E) Higher magniﬁcation of D showing an increased ratio of subcutaneous fat (ft) to skin (sk) thickness in a GHR-KO compared with a control pig.
Histological section (H&E stain) showing an increased amount of intramuscular fat in GHR-KO pigs (bar ¼ 100 mm).toward increased levels of total peroxisome proliferator-activated re-
ceptor gamma (PPARG) was observed (Figure 7A).
GHR-KO liver samples showed signiﬁcantly increased phosphorylation
levels of Janus kinase 2 (JAK2). The phosphorylation levels of signal
transducer and activator of transcription 5 (STAT5) were signiﬁcantly
reduced, while STAT3 phosphorylation showed a tendency to increase
(p ¼ 0.1111). Phosphorylation of STAT1 was not signiﬁcantly different
between GHR-KO and control pigs, whereas signiﬁcantly increased
phosphorylation levels of mitogen-activated protein kinase (MAPK)
were detected (Suppl. Fig. 5).
In addition, liver extracts from GHR-KO pigs showed a signiﬁcant in-
crease in phosphorylated mechanistic target of rapamycin (mTOR),
which was not detected in control liver samples. To distinguish be-
tween the activation of mTOR complex 1 (mTORC1) and 2 (mTORC2),
we analyzed several speciﬁc up- and downstream signal transducers
for each complex [35,36] (Figure 7B; Suppl. Fig. 5).MOLECULAR METABOLISM 11 (2018) 113e128  2018 The Authors. Published by Elsevier GmbH. This is a
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phosphorylates S6. GHR-KO liver samples did not show increased
phosphorylation of S6K (Figure 7B). Phosphorylation of other effectors
downstream of mTORC1d eukaryotic initiation factor 4E binding protein
1 (4EBP1) and eukaryotic translation initiation factor 4E (eIF4E) d was
unchanged in GHR-KO liver samples (Suppl. Fig. 5). Phosphorylation of
AMP-activated protein kinase (AMPK), an inhibitor of mTORC1, was
signiﬁcantly increased in GHR-KO liver tissue (Suppl. Fig. 5). Collectively
these data suggest that mTORC1 is not activated in liver of GHR-KO pigs.
In contrast, one of the most important downstream substrates of
mTORC2d glycogen synthase 3 beta (GSK3B)e showed signiﬁcantly
increased phosphorylation in GHR-KO liver tissue (Figure 7B).
Furthermore, the phosphorylation levels of potent regulators of
mTORC2 action, PI3K and AKT, were also increased (Figure 7A). These
ﬁndings suggest that mTORC2 is activated in the liver of GHR-deﬁcient
pigs. A summary of these ﬁndings is provided in Figure 8A.n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 119
Figure 5: Disproportionate organ growth in GHR-KO compared with control pigs. GHR-deﬁciency led to a proportionate and disproportionate reduction in organ sizes. (A)
Representative organs from control (left) and GHR-KO pigs (right). (B) Relative differences between GHR-KO and control pigs in absolute organ weights and in organ weight-to-body
weight ratios (relative organ weights). These parameters were determined in 9 GHR-KO and 25 control pigs, and least squares means (LSMs) and standard errors of LSMs were
estimated for the 2 groups (see 2.8 for the statistical model). *p < 0.05; **p < 0.01; ***p < 0.001.
Original Article3.13. Serum leptin levels and hepatic leptin receptor activation are
increased in GHR-KO pigs
Considering the expected reduced STAT5 phosphorylation but unex-
pected increased JAK2 phosphorylation in the liver of GHR-KO pigs, we
measured serum leptin levels and hepatic leptin receptor (LEPR)
activation. LEPR signaling involves activation of JAK2 and STAT3, but
not STAT5 (reviewed in [37]). Overall, serum leptin concentrations of 6-
month-old fasted GHR-KO pigs were signiﬁcantly elevated compared
with the controls (Figure 8B), with higher levels in females than in
males (Suppl. Table 2). In addition, LEPR phosphorylation was
signiﬁcantly increased in GHR-KO vs. control liver samples (Figure 8C).
4. DISCUSSION
This study reports a new large animal model for GHR deﬁciency (Laron
syndrome, LS). Previously described pig models with impaired GH
function, which are either GHR-deﬁcient [38] or express a dominant
negative GHR [39], were established on a minipig background that is
already growth impaired and, thus, may not resemble all pathophys-
iological consequences of human LS. Therefore, we established our
GHR-deﬁcient model on a German landrace background with the
physiological growth potential of domestic pigs and performed a
comprehensive characterization of body and organ growth, body
composition, endocrine and metabolic changes, and signaling cas-
cades in liver.
Our GHR-deﬁcient pig model exhibits important hallmarks of human
LS, such as insensitivity to GH, low circulating IGF1 concentrations,
and reduced postnatal body and organ growth. Similar ﬁndings have120
 2018 The Authors. Published by Elsevier GmbH. This is an open access abeen reported for minipig models with impaired GH function [38,39].
Our study provides a more comprehensive phenotypic analysis,
including serial GH measurements, effects on serum IGFBPs, age-
dependent changes in glucose homeostasis and lipid proﬁles, and
analyses of hepatic signaling cascades.
Circulating IGF1 originates in large part from the liver, as shown by liver
speciﬁc Igf1 KO mice [40], and is complexed by high-afﬁnity IGFBPs,
with IGFBP3 and an acid labile subunit (ALS) forming a 150-kDa
complex, which is the main reservoir of IGF1 in the bloodstream
(reviewed in [41,42]). ALS is directly regulated by GH, and reduced ALS
levels are observed in GHR-deﬁcient patients [43]. The production of
IGFBP3 is also stimulated by GH [44], and GHR deﬁciency in mice and
humans leads to reduced levels of IGFBP3 in the circulation [15,45]. In
agreement with these reports, serum IGFBP3 concentrations of GHR-
KO pigs were signiﬁcantly reduced, presumably leading to a decrease
in the IGF1 reservoir in the circulation and thus to a shortened half-life.
In addition, the concentration of IGFBP2 was increased in serum of
GHR-KO pigs. Studies in transgenic IGFBP2-overexpressing mice have
shown that IGFBP2 inhibits the growth of normal [46] and even of GH-
overexpressing mice [47]. Therefore, the reduced growth of GHR-KO
pigs most likely results from a combination of a decline in the pro-
duction and half-life of circulating IGF1 and, possibly, IGF1 seques-
tration by inhibitory IGFBP2.
Circulating IGF1 is also responsible for the feedback inhibition of pi-
tuitary GH secretion (reviewed in [48]). In accordance with this
concept, GHR-KO pigs with low serum IGF1 levels showed high serum
GH concentrations with partially preserved pulsatility. Serial blood
samples for the analysis of hormone proﬁles can be obtained easilyMOLECULAR METABOLISM 11 (2018) 113e128
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Figure 6: Age-dependent changes in glucose and lipid homeostasis parameters in
GHR-KO and control pigs. (A) Transient juvenile hypoglycemia in GHR-KO pigs. (B)
Unchanged serum insulin concentrations. (C) Initially lower, then higher HOMA-IR score
(interaction group*age: p < 0.05). Serum concentrations of (D) triglycerides, (E)
cholesterol, (F) low-density lipoprotein (LDL)-cholesterol, and (G) high-density lipo-
protein (HDL)-cholesterol levels were signiﬁcantly lower in young GHR-KO pigs than in
age-matched controls, but normalized with age. HDL-cholesterol levels of 23- to 27-
week-old GHR-KO pigs were even higher than in their control littermates. At least 6
animals per group and age-class were investigated. Panels AeG show least squares
means (LSMs) and standard errors of LSMs estimated for group*age (see 2.8 for the
statistical model). *p < 0.05; **p < 0.01.from pigs equipped with permanent central venous catheters [49],
whereas serial blood sampling in mice is more difﬁcult.
Interestingly, a growth deﬁciency phenotype of GHR-KO pigs was
observed no earlier than postnatal week 5, which indicated that GH
was not required as promoter of intrauterine and early postnatal
growth. This ﬁnding is consistent with observations in infants with LS
[50] and in neonatal Ghr KO mice [15]. Instead, intrauterine growth
depends on IGF2 and IGF1, with the latter acting independently of GH
during this period of development [51]. An essential role of GH as a
postnatal growth promoter is established during the maturation of the
endocrine growth axis, which is associated with an increase inMOLECULAR METABOLISM 11 (2018) 113e128  2018 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comexpression of hepatic GHR [52]. In general, intrauterine maturation of
endocrine functions in pigs is similar to humans, whereas rodents are
born in a more immature state (reviewed in [53]).
In agreement with observations in human LS patients [54] and Ghr KO
mice [55], GHR-KO pigs displayed an increase in total body fat and a
decrease in the muscle to fat ratio. Adipose tissue mass is deter-
mined by the storage and removal of triglycerides in adipocytes. A
recent study in which human adipocyte lipid age was determined by
measuring 14C from nuclear bomb tests revealed that triglycerides
are renewed up to 6 times during the average adipocyte life-span of
10 years [56]. In GHR-KO pigs, physiological adipocyte lipid turnover
is apparently disturbed at different levels. First, the lipolytic action of
GH via an increase in adipose tissue hormone-sensitive lipase (HSL)
activity (reviewed in [16,57]) is lost in the absence of GHR. Second,
the synthesis of storage lipids in adipocytes is likely to increase in
GHR-KO pigs. This phenomenon requires hydrolysis by lipoprotein
lipase (LPL) of the triglyceride component of circulating chylomicrons
and very low-density lipoproteins (VLDL) into free fatty acids and 2-
monoacylglycerol, which can be taken up by adipocytes. Adipose
tissue LPL activity is increased by insulin but inhibited by GH and sex
steroids (reviewed in [58]). Reduced serum triglyceride levels in
young GHR-KO pigs (12e15 weeks) with normal insulin levels, but
lacking the counteracting effects of GH and sex steroids, may reﬂect
an increased use of triglycerides for lipid synthesis in adipocytes,
leading to an increase in total body fat. In older GHR-KO pigs (23e27
weeks), the increased total body fat content may lead to decreased
triglyceride turnover of adipocytes [56], limiting the use of circulating
triglycerides for storage lipid synthesis in adipocytes. Furthermore,
the animals became sexually mature, with sex steroids potentially
inhibiting adipose tissue LPL and the hydrolysis of serum tri-
glycerides, thus resulting in normal serum triglyceride levels.
Decreased serum cholesterol levels, as observed in young GHR-KO
pigs, have also been reported in human LS patients [3] and Ghr KO
mice (reviewed in [16]).
Measurements of organ weights in GHR-KO pigs revealed that growth
of liver, kidneys, and heart is particularly dependent on GHR/GH ac-
tion, as their relative weights were signiﬁcantly decreased in com-
parison to control pigs. Reduced relative liver and kidney weights have
also been observed in Ghr KO mice [55], and interestingly LS patients
have disproportionately reduced cardiac dimensions [59]. The
important role of the GH/IGF1 system in the growth of these organs is
supported by their disproportionate overgrowth in conditions of GH/
IGF1 excess, as in GH-overexpressing transgenic mice [60,61] and in
patients with acromegaly [62]. In contrast, brain growth is less
dependent on intact GHR signaling, as shown by a relatively moderate
reduction in absolute brain weight and a marked increase in the
relative brain weight of GHR-KO pigs. Based on similar observations in
Ghr KO mice, Sjogren et al. [63] speculated that a large proportion of
brain growth occurs relatively early in development in a GH-
independent stage.
Patients with Laron syndrome exhibit delayed puberty, but they are
able to achieve full sexual development and reproduce [2]. In Ghr KO
mice, delayed puberty and reduced litter sizes have been observed.
The latter has been attributed to reduced ovarian function due to the
lack of IGF1 (reviewed in [16]). To assess the fertility of GHR-KO pigs, a
GHR-KO boar and a GHR-KO sow were mated, resulting in a litter of 6
healthy piglets. Although not signiﬁcant, the mean birth weight of these
piglets was 40% lower than that of GHR-KO piglets from heterozygote x
heterozygote mating, most likely because of the limited fetal growth
capacity in a smaller mother. Interestingly, GHR-KO piglets from ho-
mozygous parents showed catch-up growth and had a 33% highern open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 121
Figure 7: Western blot analysis of signaling cascades in liver samples of 6-month-old fasted GHR-KO (n ¼ 5) and control pigs (n ¼ 4). (A) Insulin receptor-related signaling
pathway and PPARG. (B) GHR- and mTOR-related signaling pathways. The box plots show medians, 25th and 75th percentiles (box), and extremes (whiskers). *p < 0.05;
p ¼ 0.0635; evaluated using the ManneWhitney U test.
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body weight at six months than GHR-KO piglets from heterozygous
parents. An explanation for this increased growth performance may be
hybrid vigor, potentially resulting from the mating of GHR-KO pigs from
two different lines (Suppl. Fig. 1).
GHR-KO pigs showed juvenile hypoglycemia that normalized when the
animals reached sexual maturity. Hypoglycemia is a hallmark of ju-
venile age LS [3,64] and has been mainly explained by the lack of
stimulatory GH effects on hepatic gluconeogenesis (reviewed in [57]).
Contrasting observations have been obtained concerning the role of
altered insulin sensitivity in the development of juvenile hypoglycemia
(reviewed in [65]). While no evidence for increased insulin sensitivity,
and even some cases of insulin-resistant diabetes mellitus, have been
reported in the Israeli cohort of LS patients [64,66], individuals from
the Ecuadorian LS cohort are more insulin-sensitive than their GHR
intact relatives [67], and no cases of diabetes mellitus were reported
[7]. The reasons for this discrepancy remain elusive [65]. Although
HOMA-IR is not a routinely established parameter to assess insulin
(in)sensitivity in pigs (reviewed in [68]), the trend (p¼ 0.0635) toward
lower HOMA-IR scores in young GHR-KO vs. control pigs suggests that
increased insulin sensitivity is a contributing factor to juvenile hypo-
glycemia, as also observed in some Ghr KO mouse models ([69];
reviewed in [16]). While the HOMA-IR scores of GHR-KO pigs
increased with age, and tended to be higher in sexually mature GHR-
KO than in age-matched control pigs (interaction group*age:
p < 0.05), there was no evidence for insulin resistance. Interestingly,
we observed increased levels of total and phosphorylated IRS1 in liver
samples from fasted adult GHR-KO pigs, which could represent a
mechanism for increased insulin sensitivity. Similar observations and
conclusions were obtained in GH-deﬁcient Ames dwarf mice with
increased insulin sensitivity [70]. Future studies involving state-of-
the-art in vivo measurements of gluconeogenesis [71] and investi-
gation of insulin sensitivity using hyperinsulinemic, euglycemic clamp
studies in juvenile and sexually mature GHR-KO and control pigs will
help to clarify the relative contributions of these mechanisms to ju-
venile hypoglycemia in LS and its normalization in adult LS patients.
Such studies can be performed more accurately in pigs than in rodent
models due to their larger size [49].
While all clinical-chemical parameters measured in the serum of GHR-
KO pigs remained within the normal reference ranges for pigs,
creatinine levels were reduced and serum urea concentrations were
increased compared with the control pigs. The serum creatinine
concentration correlates with muscle mass [72], which explains the
reduced levels in GHR-KO pigs and in LS patients [3]. Increased serum
concentrations of urea, the end product of amino acid catabolism in
mammals, have also been detected in Ghr KO mice [69] and are most
likely due to IGF1 deﬁciency and the lack of its protein anabolic action
(reviewed in [73]).
Since the liver is a major target organ for GH, we investigated al-
terations in the activity of selected hepatic signaling pathways in adult
fasted GHR-KO and control pigs. Upon binding of GH, the GHR
homodimer undergoes a conformational change that brings the
originally parallel receptor transmembrane domains into a rotated
crossover orientation, thus separating the lower parts of the trans-
membrane helices. Thereby, the two JAK2 molecules that are
associated with the membrane proximal Box1 motif of the GHR chains
are separated, and the inhibitory pseudokinase domain of one JAK2 is
removed from the kinase domain of the other JAK2 and vice versa
[74]. The kinase domains of the two JAK2 molecules can then be
transactivated and initiate tyrosine phosphorylation of the GHR cyto-
plasmic domains and STAT5, the key transcription factor mediating
most genomic actions of GH (reviewed in [75]), including stimulationMOLECULAR METABOLISM 11 (2018) 113e128  2018 The Authors. Published by Elsevier GmbH. This is a
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phosphorylation of STAT5 in liver of GHR-KO pigs was signiﬁcantly
reduced and the circulating IGF1 levels were markedly decreased
compared with control pigs. However, unexpectedly, phosphorylation
of JAK2 was signiﬁcantly increased in liver of GHR-KO pigs, together
with a signiﬁcant increase in the phosphorylation of MAPK, PI3K, and
mTOR, which are known to be e directly or indirectly e activated by
JAK2 [77].
In addition to GHR, many other class I cytokine receptors also use the
non-receptor tyrosine kinase JAK2 for signaling, including the re-
ceptors for erythropoietin, prolactin, interleukins 3, 5 and 6,
granulocyte-macrophage colony-stimulating factor, interferon-gamma,
thrombopoietin, and leptin (reviewed in [78]). GHR is abundantly
expressed in liver and can dimerize and associate with JAK2 in the
absence of GH (reviewed in [75]). Since GHR-bound JAK2 can only be
activated in the presence of GH, elimination of GHR may increase the
pool of JAK2 that can be phosphorylated by other class I cytokine
receptors. In addition, the loss of GHR may alter the abundance of
these receptors or their ligands and thus lead to increased JAK2
phosphorylation.
A candidate is leptin, since increased serum leptin levels have been
detected in LS patients [79] and in the Ghr KO mouse model (reviewed
in [16]). Leptin is known to induce the expression of its receptor in liver
[80], and leptin receptor activation involves the phosphorylation of
JAK2 and STAT3, but not STAT5 (reviewed in [37]). Consistent with this
hypothesis, we observed signiﬁcantly increased serum leptin levels
and increased expression and phosphorylation of leptin receptors in
liver of GHR-KO pigs, providing a potential explanation for the signif-
icantly increased phosphorylation of JAK2, while phosphorylation of
STAT5 was signiﬁcantly reduced.
Phosphorylation of the serine/threonine kinase mTOR that forms the
catalytic core of mTOR complex-1 (mTORC1) and mTORC2 was
signiﬁcantly increased in GHR-KO pigs. While mTOR phosphorylation
was not directly investigated in Ghr KO mice, Dominick et al. [35]
have evaluated the activities of mTORC1 and mTORC2 in fed and
fasted animals based on the phosphorylation status of downstream
substrates of these complexes. In fasted Ghr KO mice, the authors
observed reduced phosphorylation of the ribosomal protein S6, while
the phosphorylation status of S6K and 4EBP1 was unaltered
compared with control mice. In fed Ghr KO mice, the phosphorylation
status of all three indicators of mTORC1 activity was signiﬁcantly
reduced. In contrast, the phosphorylation level of several target
substrates of mTORC2, including AKT, was signiﬁcantly increased in
fasted Ghr KO vs. control mice, while this difference disappeared
after feeding [35]. The authors concluded that mTORC2 activity was
increased in Ghr KO mice e at least in fasted animals d whereas
mTORC1 activity was unaltered or reduced in fasted and fed Ghr KO
mice, respectively. Our study of liver samples from fasted GHR-KO
pigs did not reveal an increase in the phosphorylation of S6K or of
4EBP1 that would trigger its dissociation from eIF4E and allow cap-
dependent mRNA translation (reviewed in [36]). Moreover, we
observed a signiﬁcant increase in phosphorylation (¼ activation) of
the mTORC1 inhibitor AMPK [81]. Collectively, these ﬁndings argue
against a major activation of mTORC1 in liver of GHR-KO pigs. In
contrast, a signiﬁcant increase in GSK3B phosphorylation and a trend
(p¼ 0.0635) toward an increase in AKT phosphorylation suggested a
rise in the activity of mTORC2. While mTORC1 has profound effects
on mRNA translation, metabolism, and protein turnover, mTORC2
signaling is implicated in the regulation of ion transport, apoptosis,
glucose metabolism, cell migration, and cytoskeleton rearrangement
(reviewed in [36]). Future molecular proﬁling studies of liver andn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 123
Figure 8: (A) Schematic summary of the changes in phosphorylation in INSR- and GHR-related signaling molecules in liver samples of GHR-KO compared with control pigs.
*p < 0.05; p ¼ 0.0635; evaluated using the ManneWhitney U test. (B) Signiﬁcantly increased fasting serum leptin concentrations in 6-month-old GHR-KO vs. control pigs. The
ﬁgure shows the estimated least squares means (LSMs) and standard errors of the LSMs for the two groups, taking into account the effect of sex (9 male/13 female control pigs; 6
male/6 female GHR-KO pigs). **p < 0.01 for the effect of group (PROC GLM). (C) Signiﬁcantly increased expression and phosphorylation of LEPR in liver samples from GHR-KO
compared with control pigs. PC ¼ protein lysate from choroid plexus of a wild-type pig used as positive control. *p < 0.05; evaluated using the ManneWhitney U test.
Original Articleother tissues from GHR-KO and control pigs will clarify whether these
biological processes are altered in the absence of GHR signaling.
Another interesting observation in liver samples from GHR-KO pigs was
the trend (p ¼ 0.0635) toward an increased abundance of PPARG.
Discrepant ﬁndings have been reported regarding the consequences of
increased PPARG activity in liver, ranging from the promotion of hepatic
steatosis through the upregulation of genes involved in lipid uptake and
storage, to the prevention of hepatic steatosis and ﬁbrosis, possibly by
sequestering fatty acids in adipose tissue and preventing hepatic
stellate cell activation (reviewed in [82]). Studies of GHR-KO and
control pigs, e.g., after being fed a high-fat diet, may provide additional
insight into these mechanisms.
One of the most striking effects of GHR deﬁciency is the increased life-
span that has been observed in Ghr KO mice [83,84]. Moreover, pa-
tients with LS show reduced incidences of cancer and diabetes,
associated with reduced pro-aging signaling in cells incubated with124
 2018 The Authors. Published by Elsevier GmbH. This is an open access aserum derived from these patients [7]. While life expectancy studies in
humans are difﬁcult due to their long duration and to multiple con-
founding factors, they are possible in pigs, which can be maintained
under standardized conditions and have a normal life expectancy of
15e17 years (reviewed in [85]). Moreover, protective effects of GHR
deﬁciency against tumors and diabetes can be evaluated by crossing
the GHR KO mutation in existing pig models that are genetically pre-
disposed to tumor development (e.g., [86]) or (pre-)diabetes [27,87],
thus bridging the gap between rodents and humans in longevity
research with tailored large animal models. In addition to these long-
lasting in vivo experiments, the effects of GHR deﬁciency on resistance
to stress e such as UV light and heat e may be evaluated in primary
cell cultures from GHR-KO pigs, similarly to studies that have been
performed using cultured cells from dwarf mice [88].
Investigation of the neurological consequences of GHR deﬁciency is
another interesting ﬁeld, since mental retardation has been reported inMOLECULAR METABOLISM 11 (2018) 113e128
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a proportion of LS patients [2], while subjects from the Ecuadorian
cohort display normal intelligence [89] or even enhanced cognitive
performance [90]. As sophisticated methods for testing cognitive
functions of pigs are available [91], the GHR-KO pig may also serve as
a model to address these questions.
Finally, GHR-KO pigs are interesting animal models for developing and
evaluating the efﬁcacy and safety of new treatment options for LS, such
as PASylated IGF1 with a prolonged plasma half-life [92]. In addition, it
would be interesting to determine whether the phenotype of GHR-KO
pigs can be rescued by correction of the GHRmutation in a proportion of
liver cells via gene editing. In a mouse model, hydrodynamic injection
into the tail vein has been used to deliver components of a CRISPR/Cas9
system to correct a mutated fumarylacetoacetate hydrolase (Fah) gene
in hepatocytes in vivo [93]. In pigs, reﬁned techniques are available for
direct application into the liver [94,95].
In summary, GHR-KO pigs resemble important aspects of the patho-
physiology of human Laron syndrome and are thus an interesting
model for mechanistic studies and treatment trials.
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